(Reuters) – Moderna Inc said on Monday it has started a U.S. government-backed late-stage trial evaluating its COVID-19 vaccine candidate, mRNA-1273, in about 30,000 adults who do not have the respiratory illness caused by the new coronavirus.
The main goal of the study will be prevention of the symptomatic COVID-19 disease, the company said.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
